Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations.

Autor: Fencer MG; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Rutgers-New Jersey Medical School, Newark, NJ, USA. Electronic address: mgf56@njms.rutgers.edu., Krupa KA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Bleich GC; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Grumet S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Eladoumikdachi FG; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kumar S; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Kowzun MJ; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Potdevin LB; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Jazyk: angličtina
Zdroj: Clinical breast cancer [Clin Breast Cancer] 2023 Jun; Vol. 23 (4), pp. e194-e199. Date of Electronic Publication: 2023 Feb 16.
DOI: 10.1016/j.clbc.2023.02.004
Abstrakt: Background: This study aims to capture clinical and surgical practice patterns of patients with deleterious mutations in partner and localizer of BRCA2 (PALB2), checkpoint kinase 2 (CHEK2) and ataxia telangiesctasia mutated (ATM) genes.
Materials and Methods: This study is a retrospective chart review of patients with PALB2, CHEK2 or ATM mutations. Patient demographics, testing indications, management decisions, and surveillance strategies were recorded.
Results: Sixty-two patients were found to have deleterious mutations: 14 (23%) with a PALB2 mutation, 30 (48%) with a CHEK2 mutation, and 18 (29%) patients with an ATM mutation. Thirty-one (50%) patients have a history of breast cancer. Twenty-three patients were diagnosed and treated prior to genetic testing while 8 patients learned of their mutation status and breast cancer diagnosis simultaneously. Of these 8 patients, 4 sought treatment at our institution, 3 underwent bilateral mastectomy, and 1 patient opted for lumpectomy and surveillance. Thirty-one patients had no history of breast cancer. After genetic diagnosis, 3 of the 9 patients who continued clinical follow-up proceeded with bilateral prophylactic mastectomy within 2 years. Clinical surveillance continued for 23 months on average.
Conclusion: Most patients who learned of their genetic and breast cancer diagnoses simultaneously underwent bilateral mastectomy, whereas only a third of patients without cancer opted for bilateral prophylactic mastectomy.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: